Get the Stockscreener App
3.23
3.00%
-0.10
After Hours:
3.24
0.01
+0.31%
Cibus Inc stock is traded at $3.23, with a volume of 279.85K.
It is down -3.00% in the last 24 hours and up +64.80% over the past month.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
See More
Previous Close:
$3.33
Open:
$3.27
24h Volume:
279.85K
Relative Volume:
1.77
Market Cap:
$105.52M
Revenue:
$1.82M
Net Income/Loss:
$-267.63M
P/E Ratio:
-0.1602
EPS:
-20.1639
Net Cash Flow:
$-50.53M
1W Performance:
+27.67%
1M Performance:
+64.80%
6M Performance:
-33.54%
1Y Performance:
-78.21%
1-Day Range:
$3.12
$3.38
1-Week Range:
$2.51
$3.40
52-Week Range:
$1.40
$15.00
Cibus Inc Stock (CBUS) Company Profile
Name
Cibus Inc
Sector
Industry
Phone
(858) 450-0008
Address
6455 NANCY RIDGE DRIVE, SAN DIEGO
Compare CBUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBUS
Cibus Inc
|
3.23 | 82.66M | 1.82M | -267.63M | -50.53M | -20.16 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Cibus Inc Stock (CBUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-24 | Initiated | Alliance Global Partners | Buy |
| Jul-19-24 | Resumed | Canaccord Genuity | Buy |
| Oct-09-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Resumed | Canaccord Genuity | Buy |
Cibus Inc Stock (CBUS) Latest News
Transcript : Cibus, Inc. Presents at Bank of America Ag Tech Conference 2025, May-20-2025 03 - marketscreener.com
Cibus Stockholders Approve 2025 Employee Stock Plan - TipRanks
Cibus, Inc. Co-Founder Participates in BofA Securities 2025 AgTech Virtual Conference to Discuss Gene Editing Innovations and Pipeline Progression - Nasdaq
Cibus Provides Webcast of BofA Securities AgTech Virtual Conference Fireside Chat - The Manila Times
Cibus Approves Key Measures at Annual Meeting - TipRanks
Cibus at Alliance Global Partners: Strategic Gene Editing Insights - Investing.com
Cibus at Alliance Global Partners: Strategic Gene Editing Insights By Investing.com - Investing.com Nigeria
Cibus director Prante Gerhard sells $2,898 in stock - MSN
Cibus to Participate in Alliance Global Partner's Annual Virtual Healthcare Company Showcase - The Manila Times
Cibus to Participate in Alliance Global Partner's Annual Virtual Healthcare Company Showcase | CBUS Stock News - GuruFocus
Cibus, Inc. to Present Advances in Gene-Editing Technology at AGP Annual Virtual Healthcare Company Showcase - Nasdaq
Cibus to Participate in Alliance Global Partner’s Annual Virtual Healthcare Company Showcase - Bluefield Daily Telegraph
Cibus to Reveal Next-Gen Agricultural Biotech Roadmap and Commercialization Plans at Healthcare Showcase - Stock Titan
Canaccord Genuity Group Lowers Cibus (NASDAQ:CBUS) Price Target to $17.50 - MarketBeat
Cibus, Inc. (NASDAQ:CBUS) Q1 2025 Earnings Call Transcript - MSN
Cibus (NASDAQ:CBUS) Posts Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Barclays PLC Acquires 7,106 Shares of Cibus, Inc. (NASDAQ:CBUS) - Defense World
Ecuador Determines Cibus Herbicide Tolerance Rice Traits are Equivalent to Conventional Breeding - ISAAA
Raymond James Financial Inc. Purchases Shares of 32,120 Cibus, Inc. (NASDAQ:CBUS) - Defense World
Granby Capital Management LLC Acquires 150,000 Shares of Cibus, Inc. (NASDAQ:CBUS) - MarketBeat
Cibus (NASDAQ:CBUS) Given New $17.50 Price Target at Canaccord Genuity Group - Defense World
Cibus, Inc. Earnings Call: Achievements and Challenges - MSN
Cibus (CBUS) Maintained at Buy by Canaccord Genuity, Price Targe - GuruFocus
Cibus (CBUS) Maintained at Buy by Canaccord Genuity, Price Target Lowered | CBUS Stock News - GuruFocus
Cibus (CBUS) Target Price Adjusted by Canaccord Analyst Amid Revenue Challenges | CBUS Stock News - GuruFocus
Promising Growth and Market Expansion Drive Buy Rating for Cibus, Inc. - TipRanks
Cibus, Inc. (NASDAQ:CBUS) Shares Bought by Renaissance Technologies LLC - MarketBeat
Cibus Inc (CBUS) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo
Cibus, Inc. Reports Q1 2025 Financial Results and Business Progress - TipRanks
Cibus: Q1 Earnings Snapshot - The Washington Post
Cibus (CBUS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Cibus Inc Q1 2025 sees rising losses amid innovation push - Investing.com
Cibus Inc Reports Q1 2025 Revenue of $1.034 Million, Missing Analyst Estimate of $1.14 Million - GuruFocus
Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025 - The Manila Times
Ecuador Approves Cibus Herbicide Tolerance Rice Traits As Equivalent to Conventional Breeding - AgriBusiness Global
Cibus announces Ecuador approved Cibus herbicide tolerance Rice traits - TipRanks
Cibus (CBUS) Gains Approval in Ecuador for Herbicide Tolerant Rice | CBUS Stock News - GuruFocus
Ecuador Approves Cibus Herbicide Tolerance Traits as Equivalent to Conventional Breeding - The Manila Times
Cibus (CBUS) to Post Earnings on Thursday - MarketBeat
Cibus Inc expected to post a loss of 66 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Buys 114,800 Shares of Cibus, Inc. (NASDAQ:CBUS) - Defense World
Cibus director Prante sells $2,875 in stock - MSN
Cibus Inc Stock (CBUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):